Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category (Ascending) Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
25021-0254-08 25021-0254 Docetaxel Anhydrous Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug. 1, 2023 In Use
25021-0254-16 25021-0254 Docetaxel Anhydrous Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug. 1, 2023 In Use
23155-0869-41 23155-0869 Arsenic Trioxide Arsenic Trioxide 2.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Oct. 7, 2021 In Use
23155-0870-41 23155-0870 Arsenic Trioxide Arsenic Trioxide 1.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous April 22, 2022 In Use
23155-0882-31 23155-0882 Paclitaxel PACLITAXEL 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug. 31, 2023 In Use
23155-0883-31 23155-0883 Paclitaxel PACLITAXEL 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug. 31, 2023 In Use
23155-0884-31 23155-0884 Paclitaxel PACLITAXEL 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug. 31, 2023 In Use
25021-0223-20 25021-0223 Cytarabine Cytarabine 100.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intrathecal, Intravenous, Subcutaneous June 1, 2023 In Use
25021-0229-05 25021-0229 Cytarabine Cytarabine 20.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intrathecal, Intravenous, Subcutaneous June 1, 2023 In Use
25021-0250-20 25021-0250 Mitomycin Mitomycin 5.0 mg/10mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous June 15, 2023 In Use
25021-0251-50 25021-0251 Mitomycin Mitomycin 20.0 mg/40mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous June 15, 2023 In Use
25021-0252-51 25021-0252 Mitomycin Mitomycin 40.0 mg/80mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous June 15, 2023 In Use
42291-0901-28 42291-0901 Sunitinib Malate Sunitinib Malate 12.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Oct. 11, 2023 In Use
42291-0902-28 42291-0902 Sunitinib Malate Sunitinib Malate 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Oct. 11, 2023 In Use
42291-0904-28 42291-0904 Sunitinib Malate Sunitinib Malate 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Oct. 11, 2023 In Use
43598-0660-11 43598-0660 Cyclophosphamide Cyclophosphamide 500.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous July 24, 2023 In Use
43598-0661-11 43598-0661 Cyclophosphamide Cyclophosphamide 1.0 g/2mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous July 24, 2023 In Use
43598-0662-11 43598-0662 Cyclophosphamide Cyclophosphamide 2.0 g/4mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous July 24, 2023 In Use
50419-0489-01 50419-0489 Sorafenib Nexavar 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, PDGFR, KIT, RET, RET/PTC, FLT3, CRAF, BRAF Oral Oct. 2, 2023 In Use
55150-0392-01 55150-0392 BENDAMUSTINE HYDROCHLORIDE BENDAMUSTINE HYDROCHLORIDE 100.0 mg/20mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous June 5, 2023 In Use
51991-0821-28 51991-0821 Everolimus Everolimus 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral March 5, 2021 In Use
51991-0821-33 51991-0821 Everolimus Everolimus 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 5, 2023 In Use
51991-0822-28 51991-0822 Everolimus Everolimus 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral March 5, 2021 In Use
51991-0822-33 51991-0822 Everolimus Everolimus 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 5, 2023 In Use
51991-0823-28 51991-0823 Everolimus Everolimus 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral March 5, 2021 In Use
51991-0823-33 51991-0823 Everolimus Everolimus 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 5, 2023 In Use
51991-0824-28 51991-0824 Everolimus Everolimus 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Oct. 1, 2021 In Use
51991-0824-33 51991-0824 Everolimus Everolimus 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 5, 2023 In Use
54288-0164-01 54288-0164 Carboplatin CARBOPLATIN 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous July 31, 2023 In Use
54288-0165-01 54288-0165 Carboplatin CARBOPLATIN 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous July 31, 2023 In Use
54288-0166-01 54288-0166 Carboplatin CARBOPLATIN 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous July 31, 2023 In Use
54288-0167-01 54288-0167 Carboplatin CARBOPLATIN 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous July 31, 2023 In Use
55150-0391-01 55150-0391 BENDAMUSTINE HYDROCHLORIDE BENDAMUSTINE HYDROCHLORIDE 25.0 mg/5mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous June 5, 2023 In Use
57894-0050-60 57894-0050 NIRAPARIB TOSYLATE MONOHYDRATE and ABIRATERONE ACETATE AKEEGA 500.0 mg/1, 50.0 mg/1 Chemotherapy Androgen Receptor Inhibitor, Enzyme Inhibitor CYP 17, PARP Oral Aug. 11, 2023 In Use
57894-0100-60 57894-0100 NIRAPARIB TOSYLATE MONOHYDRATE and ABIRATERONE ACETATE AKEEGA 500.0 mg/1, 100.0 mg/1 Chemotherapy Androgen Receptor Inhibitor, Enzyme Inhibitor CYP17, PARP Oral Aug. 11, 2023 In Use
60505-4512-03 60505-4512 Gefitinib Gefitinib 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Aug. 8, 2023 In Use
60505-6095-00 60505-6095 Bendamustine Hydrochloride Bendamustine Hydrochloride 25.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous June 19, 2023 In Use
60505-6096-00 60505-6096 Bendamustine hydrochloride Bendamustine Hydrochloride 100.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous June 19, 2023 In Use
60505-6272-01 60505-6272 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous July 1, 2023 In Use
60505-6277-00 60505-6277 CISplatin CISplatin 50.0 mg/50mL Chemotherapy Alkylating Agent Platinum Compound Intravenous June 6, 2023 In Use
62135-0772-35 62135-0772 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Aug. 29, 2023 In Use
63304-0116-13 63304-0116 Pazopanib Pazopanib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, PDGFR, FGFR, Kit, Itk, Lck, c-Fms Oral Oct. 20, 2023 In Use
63304-0116-30 63304-0116 Pazopanib Pazopanib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, PDGFR, FGFR, Kit, Itk, Lck, c-Fms Oral Oct. 20, 2023 In Use
63539-0051-30 63539-0051 Talazoparib Talzenna 0.5 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 21, 2023 In Use
63759-3048-01 63759-3048 Pemetrexed disodium Pemetrexed 100.0 mg/10mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 3, 2023 In Use
63759-3049-01 63759-3049 Pemetrexed disodium Pemetrexed 500.0 mg/50mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 3, 2023 In Use
63759-3050-01 63759-3050 Pemetrexed disodium Pemetrexed 1000.0 mg/100mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 3, 2023 In Use
63850-0058-01 63850-0058 Everolimus Everolimus 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral March 5, 2021 In Use
63850-0058-04 63850-0058 Everolimus Everolimus 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral May 26, 2023 In Use
63850-0059-01 63850-0059 Everolimus Everolimus 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral March 5, 2021 In Use

Found 10,000 results in 5 milliseconds — Export these results